Wong ECL - Search Results

1

Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.

Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Narula N, et al. Among authors: wong ecl. J Crohns Colitis. 2021 Mar 5;15(3):462-470. doi: 10.1093/ecco-jcc/jjaa189. J Crohns Colitis. 2021. PMID: 32931556

2

Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.

Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Narula N, et al. Among authors: wong ecl. Am J Gastroenterol. 2020 Aug;115(8):1236-1245. doi: 10.14309/ajg.0000000000000617. Am J Gastroenterol. 2020. PMID: 32759621

3

Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial.

Wong ECL, Marshall JK, Reinisch W, Narula N. Wong ECL, et al. Inflamm Bowel Dis. 2021 May 17;27(6):848-854. doi: 10.1093/ibd/izaa214. Inflamm Bowel Dis. 2021. PMID: 32812022 Clinical Trial.

4

End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.

Wong ECL, Buffone E, Lee SJ, Dulai PS, Marshall JK, Reinisch W, Narula N. Wong ECL, et al. J Crohns Colitis. 2021 Jul 5;15(7):1114-1119. doi: 10.1093/ecco-jcc/jjaa242. J Crohns Colitis. 2021. PMID: 33245751 Free PMC article.

5

Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.

Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Narula N, et al. Among authors: wong ecl. J Crohns Colitis. 2021 Oct 7;15(10):1649-1657. doi: 10.1093/ecco-jcc/jjab045. J Crohns Colitis. 2021. PMID: 33693522

6

Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).

Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai PS. Narula N, et al. Among authors: wong ecl. Gut. 2022 Jun;71(6):1078-1087. doi: 10.1136/gutjnl-2020-323799. Epub 2021 Mar 25. Gut. 2022. PMID: 33766910

7

Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.

Narula N, Wong ECL, Dulai PS, Sengupta NK, Marshall JK, Colombel JF, Reinisch W. Narula N, et al. Among authors: wong ecl. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1579-1587.e2. doi: 10.1016/j.cgh.2021.04.006. Epub 2021 Apr 7. Clin Gastroenterol Hepatol. 2022. PMID: 33838348 Clinical Trial.

8

Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.

Narula N, Wong ECL, AlRamdan R, Bualbanat H, Marshall JK, Steinhart AH, Greener T, Silverberg MS. Narula N, et al. Among authors: wong ecl. J Gastroenterol Hepatol. 2021 Oct;36(10):2803-2812. doi: 10.1111/jgh.15551. Epub 2021 May 31. J Gastroenterol Hepatol. 2021. PMID: 34020510

9

Reply.

Wong ECL, Dulai PS, Sengupta NK, Marshall JK, Colombel JF, Reinisch W, Narula N. Wong ECL, et al. Clin Gastroenterol Hepatol. 2022 May;20(5):e1216-e1217. doi: 10.1016/j.cgh.2021.05.051. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 34058410 No abstract available.

10

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.

Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. Narula N, et al. Among authors: wong ecl. United European Gastroenterol J. 2021 Jun;9(5):581-589. doi: 10.1002/ueg2.12094. Epub 2021 Jun 2. United European Gastroenterol J. 2021. PMID: 34077627 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page